Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome.
BACKGROUND
Drug-induced hypersensitivity syndrome (DIHS) is characterized by a severe multiorgan hypersensitivity reaction that usually appears after a 3-6-week exposure to certain drugs, including anticonvulsants. There are some reports showing that serum IgG levels often decrease at the early stage of DIHS. Reactivation of human herpesvirus (HHV)-6 has been reported in patients with DIHS, and some other DIHS patients showed reactivation of cytomegalovirus (CMV) or Epstein-Barr virus (EBV).


OBJECTIVE
To determine whether reactivation of HHV-6, HHV-7, CMV and/or EBV occurs in patients with DIHS.


METHODS
Titres of IgG and IgM antibodies to HHV-6 and HHV-7 were determined using an indirect immunofluorescence antibody assay on admission and at various times after admission. Anti-CMV IgG and IgM antibody titres and anti-EBV capsid antigen IgG, IgA, IgM, and EBV nuclear antigen and EBV early antigen IgG titres were determined by enzyme immunoassay. Polymerase chain reaction (PCR) procedures for HHV-6, HHV-7, CMV and EBV DNAs were performed using serum samples. IgG antibody titres to HHV-6, HHV-7, CMV and EBV were increased after the onset in seven, six, seven and two of seven patients, respectively. IgG antibody titres to HHV-6 and HHV-7 were elevated simultaneously 21-38 days after the onset.


RESULTS
IgG antibody titres to CMV and EBV were elevated 10-21 days after the elevation of HHV-6 and HHV-7 antibody titres. PCR showed that HHV-6, HHV-7, CMV and EBV DNAs became positive in six, five, seven and two of seven patients, respectively. HHV-6 and HHV-7 DNAs were detected 21-35 days after the onset, and CMV DNA was detected 10-21 days after detection of HHV-6 and HHV-7 DNAs.


CONCLUSIONS
The present study suggests that in addition to HHV-6 reactivation, reactivation of HHV-7, CMV and/or EBV may also occur following drug eruption in some patients with DIHS.
Seishima
M
M
Department of Dermatology, Ogaki Municipal Hospital, Minaminokawa-cho 4-86, Ogaki City 503-8502, Japan. marikoseishima@yahoo.co.jp
Yamanaka
S
S
Fujisawa
T
T
Tohyama
M
M
Hashimoto
K
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood; D003587:Cytomegalovirus / Q000276:immunology / Q000302:isolation & purification / Q000502:physiology; D004279:DNA, Viral / Q000097:blood; D003875:Drug Eruptions / Q000821:virology; D004342:Drug Hypersensitivity / Q000821:virology*; D005260:Female; D006564:Herpesviridae / Q000276:immunology / Q000302:isolation & purification / Q000502:physiology*; D006566:Herpesviridae Infections / Q000150:complications* / Q000821:virology; D004854:Herpesvirus 4, Human / Q000276:immunology / Q000302:isolation & purification / Q000502:physiology; D015654:Herpesvirus 6, Human / Q000276:immunology / Q000302:isolation & purification / Q000502:physiology; D016199:Herpesvirus 7, Human / Q000276:immunology / Q000302:isolation & purification / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D014775:Virus Activation
D000914:Antibodies, Viral; D004279:DNA, Viral